|Source||Humanized (from mouse)|
|Chemical and physical data|
|Molar mass||146.0 kg/mol g·mol−1|
|(what is this?)|
Benralizumab (INN, trade name Fasenra) is a monoclonal antibody which developed by MedImmune for the treatment of asthma. It is directed against the alpha-chain of the interleukin-5 receptor (CD125).
Two Phase 3 clinical trials of benralizumab, SIROCCO and CALIMA, reported meeting their primary endpoints in 2016. It was approved by the US FDA in November 2017 for the treatment of severe eosinophilic asthma. It was also granted orphan drug designation by the FDA for treatment of eosinophilic oesophagitis in August 2019.
- Statement on an Nonproprietary Name adopted by the USAN Counil: Benralizumab
- Catley MC (September 2010). "Asthma & COPD--IQPC's Second Conference". IDrugs. 13 (9): 601–4. PMID 20799138.
- AstraZeneca's benralizumab reduces asthma exacerbations up to 51% in two late-state studies. Sept 2016
- Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, et al. (June 2017). "Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma". The New England Journal of Medicine. 376 (25): 2448–2458. doi:10.1056/NEJMoa1703501. PMID 28530840.
- "Fasenra (benralizumab) receives US FDA approval for severe eosinophilic asthma". AstraZeneca. 2017-11-14.
- "Fasenra granted US Orphan Drug Designation for eosinophilic oesophagitis". www.astrazeneca.com. Retrieved 2019-10-29.
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|
|This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.|